Combination Therapy Strategies and Advanced Biomarkers Can Potentially Enhance The Precision-Medicine Treatment of Metastatic Breast Cancer

Abstract

Background: Breast cancer treatment often involves a combination of different therapeutic techniques to effectively target the disease and overcome resistance mechanisms. This multimodal approach enhances the potency and efficacy of the treatment. Methods: The multimodality therapy for breast cancer includes the integration of chemotherapy, targeted therapy, hormone therapy, and immunotherapy. This comprehensive strategy blocks various pathways concurrently, thus circumventing mechanisms responsible for resistance. Chemotherapy combined with targeted medicine, which impedes biochemical processes crucial for cancer progression, is highlighted as a potentially superior approach. Results: Oncologists are increasingly employing novel biomarkers to identify specific molecular differences responsible for cancer development. Medications such as PARP inhibitors for breast cancers with BRCA mutations and HER2-targeted therapies for HER2-positive tumors have shown effectiveness. Emerging biomarkers, including circulating tumor DNA (ctDNA) and gene expression profiles, provide real-time insights into tumor status and treatment efficacy. Conclusion: The use of multimodality therapy in breast cancer, which leverages various treatment techniques and novel biomarkers, holds promise for more effective and personalized treatment strategies. The incorporation of emerging biomarkers in treatment decision-making processes can significantly improve outcomes by providing current information on tumor characteristics and response to therapy.